Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist

In this article we will review the role of long acting β2-adrenoreceptor agonists and long-acting muscarinic agents in the management of airflow obstruction. We will then focus our attention on indacaterol, one of the new once daily inhaled β2-adrenoreceptor agonists. Pharmacologically this drug is...

Descripción completa

Detalles Bibliográficos
Autores principales: Roig, Jorge, Hernando, Rosana, Mora, Ramon
Formato: Texto
Lenguaje:English
Publicado: Bentham Open 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682927/
https://www.ncbi.nlm.nih.gov/pubmed/19452036
http://dx.doi.org/10.2174/1874306400903010027
_version_ 1782167105548845056
author Roig, Jorge
Hernando, Rosana
Mora, Ramon
author_facet Roig, Jorge
Hernando, Rosana
Mora, Ramon
author_sort Roig, Jorge
collection PubMed
description In this article we will review the role of long acting β2-adrenoreceptor agonists and long-acting muscarinic agents in the management of airflow obstruction. We will then focus our attention on indacaterol, one of the new once daily inhaled β2-adrenoreceptor agonists. Pharmacologically this drug is a nearly full β2-agonist without loss of efficacy after prolonged administration. We will also discuss its dosing, safety and tolerability.
format Text
id pubmed-2682927
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-26829272009-05-18 Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist Roig, Jorge Hernando, Rosana Mora, Ramon Open Respir Med J Article In this article we will review the role of long acting β2-adrenoreceptor agonists and long-acting muscarinic agents in the management of airflow obstruction. We will then focus our attention on indacaterol, one of the new once daily inhaled β2-adrenoreceptor agonists. Pharmacologically this drug is a nearly full β2-agonist without loss of efficacy after prolonged administration. We will also discuss its dosing, safety and tolerability. Bentham Open 2009-03-12 /pmc/articles/PMC2682927/ /pubmed/19452036 http://dx.doi.org/10.2174/1874306400903010027 Text en © Roig et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Roig, Jorge
Hernando, Rosana
Mora, Ramon
Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
title Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
title_full Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
title_fullStr Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
title_full_unstemmed Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
title_short Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
title_sort indacaterol, a novel once daily inhaled β2-adrenoreceptor agonist
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682927/
https://www.ncbi.nlm.nih.gov/pubmed/19452036
http://dx.doi.org/10.2174/1874306400903010027
work_keys_str_mv AT roigjorge indacaterolanoveloncedailyinhaledb2adrenoreceptoragonist
AT hernandorosana indacaterolanoveloncedailyinhaledb2adrenoreceptoragonist
AT moraramon indacaterolanoveloncedailyinhaledb2adrenoreceptoragonist

Ejemplares similares